Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients - PubMed (original) (raw)
Review
Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients
Christopher O'Regan et al. Am J Med. 2008 Jan.
Abstract
Purpose: More than 120,000 patients now have taken part in randomized trials evaluating statin therapy for stroke prevention. We aimed to conduct a comprehensive review of all randomized trials and determine the therapeutic potential of statins for all strokes.
Methods: We searched 10 electronic databases (from inception to December 2006). We additionally contacted study authors and authors of previous reviews. We extracted data on study characteristics and outcomes related to all-cause mortality, all-stroke incidence, specific type of strokes, and cholesterol changes. We pooled data using a random-effects model and conducted meta-regression.
Results: We included 42 trials assessing statin therapy for all-stroke prevention (n=121,285), resulting in a pooled relative risk (RR) of 0.84 (95% confidence interval [CI], 0.79-0.91). The pooled RR of statin therapy for all-cause mortality (n=116,080) was 0.88 (95% CI, 0.83-0.93). Each unit increase in low-density lipoprotein (LDL) resulted in a 0.3% increased RR of death (P=.02). Seventeen trials evaluated statins on cardiovascular death (n=57,599, RR 0.81, 95% CI, 0.74-0.90), and 11 evaluated nonhemorrhagic cerebrovascular events (n=58,604, RR 0.81, 95% CI, 0.69-0.94). Eleven trials reported hemorrhagic stroke incidence (total n=54,334, RR 0.94, 95% CI, 0.68-1.30) and 21 trials reported on fatal strokes (total n=82,278, RR 0.99, 95% CI, 0.80-1.21). Only one trial reported on statin therapy for secondary prevention.
Conclusions: Statin therapy provides high levels of protection for all-cause mortality and nonhemorrhagic strokes. This overview reinforces the need to consider prolonged statin treatment in patients at high risk of major vascular events, but caution remains for patients at risk of bleeds.
Comment in
- Review: statins prevent stroke and reduce mortality.
Hankey GJ. Hankey GJ. ACP J Club. 2008 Jul;149(1):7. ACP J Club. 2008. PMID: 18624375 No abstract available. - Review: statins prevent stroke and reduce mortality.
Hankey GJ. Hankey GJ. Evid Based Med. 2008 Aug;13(4):113. doi: 10.1136/ebm.13.4.113. Evid Based Med. 2008. PMID: 18667672 No abstract available.
Similar articles
- Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Mills EJ, et al. J Am Coll Cardiol. 2008 Nov 25;52(22):1769-81. doi: 10.1016/j.jacc.2008.08.039. J Am Coll Cardiol. 2008. PMID: 19022156 - Impact of statins on risk of stroke: a meta-analysis.
Henyan NN, Riche DM, East HE, Gann PN. Henyan NN, et al. Ann Pharmacother. 2007 Dec;41(12):1937-45. doi: 10.1345/aph.1K280. Epub 2007 Nov 6. Ann Pharmacother. 2007. PMID: 17986516 - Effectiveness of statin therapy in adults with coronary heart disease.
Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A. Wilt TJ, et al. Arch Intern Med. 2004 Jul 12;164(13):1427-36. doi: 10.1001/archinte.164.13.1427. Arch Intern Med. 2004. PMID: 15249352 Review. - [Does statin therapy reduce the risk of stroke? A meta-analysis].
Sirol M, Bouzamondo A, Sanchez P, Lechat P. Sirol M, et al. Ann Med Interne (Paris). 2001 Apr;152(3):188-93. Ann Med Interne (Paris). 2001. PMID: 11431579 French. - Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
Briel M, Studer M, Glass TR, Bucher HC. Briel M, et al. Am J Med. 2004 Oct 15;117(8):596-606. doi: 10.1016/j.amjmed.2004.04.022. Am J Med. 2004. PMID: 15465509 Review.
Cited by
- Evaluation of Transient Ischemic Stroke Cases Admitted to a Tertiary Hospital in Mehedinți County, South-West of Romania.
Păun O, Mogoantă L. Păun O, et al. Curr Health Sci J. 2023 Jul-Sep;49(3):325-332. doi: 10.12865/CHSJ.49.03.04. Epub 2023 Sep 30. Curr Health Sci J. 2023. PMID: 38314215 Free PMC article. - Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus.
Yu JM, Chen WM, Shia BC, Wu SY. Yu JM, et al. Curr Atheroscler Rep. 2023 Sep;25(9):619-628. doi: 10.1007/s11883-023-01135-w. Epub 2023 Jul 29. Curr Atheroscler Rep. 2023. PMID: 37515725 Review. - Statin Use and Stroke Rate in Older Adults With Atrial Fibrillation: A Population-Based Cohort Study.
Shweikialrefaee B, Ko DT, Fang J, Pang A, Austin PC, Dorian P, Singh SM, Jackevicius CA, Tu K, Lee DS, Abdel-Qadir H. Shweikialrefaee B, et al. J Am Heart Assoc. 2023 Jun 20;12(12):e028381. doi: 10.1161/JAHA.122.028381. Epub 2023 Jun 15. J Am Heart Assoc. 2023. PMID: 37318025 Free PMC article. - Independent and Joint Association of Statin Therapy with Adverse Outcomes in Heart Failure Patients with Atrial Fibrillation Treated with Cardiac Resynchronization Therapy.
Yu Y, Ding L, Deng Y, Huang H, Cheng S, Cai C, Gu M, Chen X, Ning X, Niu H, Hua W. Yu Y, et al. J Inflamm Res. 2022 Dec 9;15:6645-6656. doi: 10.2147/JIR.S390127. eCollection 2022. J Inflamm Res. 2022. PMID: 36532652 Free PMC article. - Impact of Low-density Lipoprotein Cholesterol Levels on Outcomes in Nonvalvular Atrial Fibrillation: Results from the China Atrial Fibrillation Registry Study.
Li ZZ, Du X, Liu N, Guo XY, Jiang C, He L, Xia SJ, Wang W, Tang RB, Chang SS, Yu RH, Long DY, Bai R, Sang CH, Li SN, Dong JZ, Ma CS. Li ZZ, et al. Med Sci Monit. 2022 Apr 14;28:e934747. doi: 10.12659/MSM.934747. Med Sci Monit. 2022. PMID: 35418552 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical